Source: Annual Congress 2011 - Molecular biomarkers at the bedside of critically ill patients
Disease area: Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
A. Artigas (Sabadell, Spain). Are biomarkers helpful in sepsis for risk assessment or clinical trials?. Annual Congress 2011 - Molecular biomarkers at the bedside of critically ill patients

Member's Comments

No comment yet.

Related content which might interest you: Emerging concepts in outcome assessment for COPD clinical trials Source: Annual Congress 2007 - PG13 - Outcome measures of clinical trials for new drugs for respiratory disease Year: 2007 Importance of admission biomarkers in prognostication of  patients with SARS-Cov-2 Source: Virtual Congress 2021 – COVID-19 and acute respiratory failure Year: 2021 Risk stratification of pulmonary embolism: clinical evaluation, biomarkers or both? Source: Eur Respir J 2015; 46: 1551-1553 Year: 2015 Determining the best diagnostic biomarker for sepsis and prognosis assessment Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012 Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies Year: 2009 Do the current endpoints in IPF clinical trials allow good regulatory decisions to be made? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014 What requirements should a biomarker meet to be used in the clinical and epidemiological setting? Source: Annual Congress 2008 - Biomarkers in COPD - application in clinical and epidemiological studies Year: 2008 The clinical and prognostic evaluation of patients with PAH Source: Annual Congress 2012 - Exercise testing in pulmonary arterial hypertension patients Year: 2012 Harvesting biomarkers for early risk assessment Source: Annual Congress 2008 - New age lung carcinogenesis: clinical impact Year: 2008 Blood biomarker algorithms to guide COPD assessment and risk stratification Source: International Congress 2017 – Towards personalised medicine in COPD: biological and clinical phenotypes Year: 2017 The clinical role of routine non-invasive parameters in the diagnostic work-up of patients with risk for pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical diagnosis, treatment, end-points and animal models Year: 2012 COPD treatment from pathophysiology to clinical trials Source: ERS Live 2007 Year: 2007 Measuring inflammation inpaediatric severe asthma: biomarkers in clinical practice Source: Breathe, 16 (1) 190301; 10.1183/20734735.0301-2019 Year: 2020 An international prospective cohort study to develop a practical COPD disease risk index that predicts the clinical course of COPD Source: Annual Congress 2009 - Comorbidities and case management in primary respiratory care Year: 2009 Does clinical score evaluation improve management in bronchiolitis patients? Source: Eur Respir J 2007; 30: Suppl. 51, 391s Year: 2007 Are asthma symptom intensity scales better than biomarkers for diagnosing asthma? A prospective observational study Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021 Biomarkers for clinical management Source: International Congress 2017 – PG12 Life-threatening pulmonary infections Year: 2017 Development of a clinical decision support system for severity risk prediction and triage of COVID-19 patients at hospital admission: an international multicentre study Source: Eur Respir J, 56 (2) 2001104; 10.1183/13993003.01104-2020 Year: 2020